Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of “Buy” by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been assigned an average recommendation of “Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $31.80.

A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada dropped their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, April 21st. Citigroup boosted their target price on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Chardan Capital boosted their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, HC Wainwright boosted their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 5th.

Insider Transactions at Eyepoint Pharmaceuticals

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the business’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 4.46% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Cyndeo Wealth Partners LLC boosted its stake in shares of Eyepoint Pharmaceuticals by 3.4% in the 4th quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock valued at $420,000 after purchasing an additional 760 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares in the last quarter. RWC Asset Management LLP boosted its stake in shares of Eyepoint Pharmaceuticals by 6.4% in the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock valued at $315,000 after purchasing an additional 1,040 shares in the last quarter. MCF Advisors LLC boosted its stake in shares of Eyepoint Pharmaceuticals by 8.3% in the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock valued at $273,000 after purchasing an additional 1,149 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after purchasing an additional 1,177 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Trading Up 3.2%

Shares of EYPT stock opened at $13.35 on Wednesday. Eyepoint Pharmaceuticals has a 1 year low of $5.57 and a 1 year high of $19.11. The firm’s fifty day simple moving average is $13.44 and its 200 day simple moving average is $14.70. The firm has a market capitalization of $1.12 billion, a P/E ratio of -3.81 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.35 million. Equities research analysts anticipate that Eyepoint Pharmaceuticals will post -3.16 EPS for the current fiscal year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.